Rituximab Terminated Phase 1 Trials for Chronic Lymphocytic Leukemia (CLL) - Refractory / B-Cell Chronic Lymphocytic Leukemia / Leukemia, Prolymphocytic Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT0009848817-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia